Rui'ang Gene's Two Fusion Gene Detection Kits See Rapid Sales Growth in 2025

GateNews
According to Rui'ang Gene's official disclosure on May 25, two newly launched fusion gene detection kits saw rapid sales growth in 2025, with significant new hospital customers added during the market expansion phase. The company's leukemia-related 15-type fusion gene detection kit and BCR-ABL P210 fusion gene detection kit, both using fluorescence RT-PCR technology, are in the fast market penetration stage.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments